Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach By: CNBC.com News June 07, 2024 at 18:20 PM EDT The FDA's expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna. Read More >> Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach By: CNBC.com News June 07, 2024 at 18:20 PM EDT The FDA's expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna. Read More >>